| Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia E Piovan, J Yu, V Tosello, D Herranz, A Ambesi-Impiombato, AC Da Silva, ... Cancer cell 24 (6), 766-776, 2013 | 279 | 2013 |
| CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance LA Pitt, AN Tikhonova, H Hu, T Trimarchi, B King, Y Gong, ... Cancer cell 27 (6), 755-768, 2015 | 261 | 2015 |
| Multivalent small-molecule pan-RAS inhibitors ME Welsch, A Kaplan, JM Chambers, ME Stokes, PH Bos, A Zask, ... Cell 168 (5), 878-889. e29, 2017 | 260 | 2017 |
| Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives J Xu, P Yang, S Xue, B Sharma, M Sanchez-Martin, F Wang, KA Beaty, ... Human genetics 138 (2), 109-124, 2019 | 224 | 2019 |
| The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia M Sanchez-Martin, A Ferrando Blood, The Journal of the American Society of Hematology 129 (9), 1124-1133, 2017 | 224 | 2017 |
| Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia Nature Medicine, 2015 | 205 | 2015 |
| Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia K Oshima, H Khiabanian, AC da Silva-Almeida, G Tzoneva, F Abate, ... Proceedings of the National Academy of Sciences 113 (40), 11306-11311, 2016 | 193 | 2016 |
| RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis JR Cortes, A Ambesi-Impiombato, L Couronné, SA Quinn, CS Kim, ... Cancer cell 33 (2), 259-273. e7, 2018 | 182 | 2018 |
| Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia G Tzoneva, CL Dieck, K Oshima, A Ambesi-Impiombato, ... Nature 553 (7689), 511-514, 2018 | 109 | 2018 |
| Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias K Wang, M Sanchez-Martin, X Wang, KM Knapp, R Koche, L Vu, ... Leukemia 31 (1), 151-158, 2017 | 77 | 2017 |
| Synergistic antileukemic therapies in NOTCH1-induced T-ALL Sanchez-Martin M, Ambesi-Impiombato A, Q Y, H D, B M, G T, P E, T MS, ... PNAS, 2017 | 64 | 2017 |
| Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma L Arnes, Z Liu, J Wang, C Maurer, I Sagalovskiy, M Sanchez-Martin, ... Gut 68 (3), 499-511, 2019 | 48 | 2019 |
| Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma RR Luis Arnes, Zhaoqi Liu, Jiguang Wang,Hans Carlo Maurer, Irina ... Gut, 2018 | 48* | 2018 |
| Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications M Sanchez‐Martin, A Pandiella International journal of cancer 131 (1), 244-252, 2012 | 48 | 2012 |
| Structure and mechanisms of NT5C2 mutations driving thiopurine resistance in relapsed lymphoblastic leukemia CL Dieck, G Tzoneva, F Forouhar, Z Carpenter, A Ambesi-Impiombato, ... Cancer Cell 34 (1), 136-147. e6, 2018 | 47 | 2018 |
| Therapeutic targeting of HES1 transcriptional programs in T-ALL SA Schnell, A Ambesi-Impiombato, M Sanchez-Martin, L Belver, L Xu, ... Blood, The Journal of the American Society of Hematology 125 (18), 2806-2814, 2015 | 46 | 2015 |
| Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias Blood, 2015 | 42* | 2015 |
| Leukemia-specific delivery of mutant NOTCH1 targeted therapy G Roti, J Qi, S Kitara, M Sanchez-Martin, A Saur Conway, AC Varca, A Su, ... Journal of Experimental Medicine 215 (1), 197-216, 2018 | 36 | 2018 |
| The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia CL Furness, MB Mansur, VJ Weston, L Ermini, FW van Delft, S Jenkinson, ... Leukemia 32 (9), 1984-1993, 2018 | 31 | 2018 |
| Jak-STAT inhibition mediates romidepsin and mechlorethamine synergism in cutaneous T-cell lymphoma JR Cortes, CC Patrone, SA Quinn, Y Gu, M Sanchez-Martin, A Mackey, ... Journal of Investigative Dermatology 141 (12), 2908-2920. e7, 2021 | 17 | 2021 |
Daniel HerranzAssociate Professor of Pharmacology and Pediatrics, Rutgers Cancer Institute of New JerseyVerified email at cinj.rutgers.edu
